|
|
 |
|
Viewing report
|
|
|
|
R&D Trends: Insulin Antidiabetics - The Future is Analogs
Datamonitor, May 2011, Pages: 45
The insulin antidiabetic pipeline can be split between small manufacturers, often targeting reformulations of existing insulin, and major manufacturers pursuing novel insulin analogs. Pipeline products will need to show improvements in the clinical safety/side-effect profile of insulins, as change in delivery method alone will not be enough to gain market share.
Features and benefits
- Comprehensive analysis of the current insulin antidiabetic pipeline including both reformulations of marketed insulins and novel analog products.
- Establish the minimum acceptable and target product profiles necessary for success in the insulins market
- Assess future directions in insulin therapies in diabetes.
- Provide insight into clinical trial design and trends in insulin antidiabetics
Highlights
- The insulin pipeline consists of 26 clinical trial candidates, of which 20 are in Phase I or Phase II development. Small manufacturers are developing reformulations of human insulin to improve delivery or pharmacological profile, while major insulin players are focusing entirely on analog insulins and combinations.
- Comparator insulins Lantus, NovoRapid, and Novomix are well accepted in the market, but pipeline products can target unmet needs associated with clinical safety and side effects, particularly by reducing hypoglycemia and reducing weight gain.
- A key future trend in insulin use is the growing utilization of technology: sophisticated pen injectors are replacing traditional vial and syringe delivery, and the use of insulin pumps to deliver a calibrated dose regime is growing.
Your key questions answered
- Datamonitor’s updated, comprehensive overview of the diabetes pipeline.
- Assess the remaining market opportunities and barriers to uptake for novel insulin therapies and formulations.
- Identify clinical trial requirements and trends in insulin antidiabetics.
|
|
|
|
